4873 English

Scandion Oncology has been very active of late, which has had significant effect on the company share. BioStock was happy to welcome CEO Nils Brünner back to the BioStock studio to give us some background about the company and discuss what makes Scandion Oncology an attractive investment.  

Watch the full interview with Scandion Oncology’s CEO Nils Brünner below.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev